[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-001", "question": "A 4-year-old boy presents with recurrent bacterial infections since infancy, including pneumonia and otitis media. Laboratory evaluation reveals absent CD19+ B cells, normal T cell numbers with preserved proliferation to mitogens, and undetectable serum immunoglobulins. Genetic testing identifies a mutation in a cytoplasmic tyrosine kinase essential for B cell development. His 2-year-old brother is asymptomatic but has the same mutation. Which of the following best explains the brother's lack of clinical manifestations?", "options": ["Residual maternal IgG providing passive immunity", "Somatic mosaicism with partial gene function restoration", "Compensatory upregulation of alternative signaling pathways", "X-chromosome inactivation favoring the wild-type allele", "Presence of a hypomorphic rather than null mutation"], "answer": "A", "answer_index": 0, "explanation": "This case describes X-linked agammaglobulinemia (XLA) due to BTK mutation. At age 2, the asymptomatic brother may still have residual transplacentally acquired maternal IgG, which typically wanes by 6-9 months but can persist longer in some cases, providing temporary protection. X-chromosome inactivation is irrelevant as this is an X-linked recessive condition affecting males who have only one X chromosome. Somatic mosaicism and hypomorphic mutations would show some B cell development, which is absent here.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (no answer defensible)\\nVerdict on keyed answer: Misleading/incorrect; no option is clearly defensible given the brother’s age and data.\\nKey stem clues: 4-year-old boy with absent CD19+ B cells, undetectable immunoglobulins, BTK mutation → classic X-linked agammaglobulinemia. Brother is 2 years old, has the *same mutation* and is asymptomatic. In XLA, transplacental maternal IgG wanes by ~6–9 months; by age 2, maternal IgG is gone and he would also lack endogenous Ig production, so option A cannot explain his being well. The stem gives no brother-specific lab data to suggest partial function (E) or mosaicism (B), and X-inactivation (D) does not apply to males. “Compensatory upregulation” (C) is speculative and not a recognized mechanism explaining an asymptomatic male with a proven BTK mutation.\\nMain logical issue(s): The question asks for a mechanistic explanation but provides no supporting evidence for any choice; the keyed answer is physiologically untenable at age 2.\\nMain medical accuracy issue(s): Overstatement that maternal IgG can meaningfully protect to age 2.\\nMinimal fix: Change brother’s age to 4–6 months and explicitly state that he has normal IgG levels derived from mother, then A becomes defensible, or provide specific lab evidence supporting a different mechanism.\\n\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (no answer defensible)\nVerdict on keyed answer: Misleading/incorrect; no option is clearly defensible given the brother’s age and data.\nKey stem clues: 4-year-old boy with absent CD19+ B cells, undetectable immunoglobulins, BTK mutation → classic X-linked agammaglobulinemia. Brother is 2 years old, has the *same mutation* and is asymptomatic. In XLA, transplacental maternal IgG wanes by ~6–9 months; by age 2, maternal IgG is gone and he would also lack endogenous Ig production, so option A cannot explain his being well. The stem gives no brother-specific lab data to suggest partial function (E) or mosaicism (B), and X-inactivation (D) does not apply to males. “Compensatory upregulation” (C) is speculative and not a recognized mechanism explaining an asymptomatic male with a proven BTK mutation.\nMain logical issue(s): The question asks for a mechanistic explanation but provides no supporting evidence for any choice; the keyed answer is physiologically untenable at age 2.\nMain medical accuracy issue(s): Overstatement that maternal IgG can meaningfully protect to age 2.\nMinimal fix: Change brother’s age to 4–6 months and explicitly state that he has normal IgG levels derived from mother, then A becomes defensible, or provide specific lab evidence supporting a different mechanism.\n", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-002", "question": "A 58-year-old woman with metastatic melanoma receiving combination ipilimumab and nivolumab develops acute onset confusion, fever to 39.2°C, and neck stiffness on day 21 of treatment. CSF analysis shows 180 WBC/μL (92% lymphocytes), protein 156 mg/dL, glucose 52 mg/dL (serum 98 mg/dL), and negative Gram stain. MRI brain shows leptomeningeal enhancement. CSF cytology and flow cytometry are negative for malignant cells. Which additional CSF finding would most strongly support the diagnosis of immune checkpoint inhibitor-induced aseptic meningitis over infectious or neoplastic etiologies?", "options": ["Elevated CSF adenosine deaminase level", "Presence of oligoclonal bands with matched serum bands", "Markedly elevated CSF IL-17 levels", "CD4+/CD8+ T cell ratio greater than 4:1 with activated phenotype", "Elevated CSF beta-2 microglobulin"], "answer": "D", "answer_index": 3, "explanation": "Immune checkpoint inhibitor-induced aseptic meningitis characteristically shows a CD4+ predominant lymphocytic pleocytosis with activated T cell phenotype (expressing HLA-DR, CD69), reflecting the mechanism of enhanced T cell activation. Elevated ADA suggests tuberculosis; oligoclonal bands suggest MS or infectious processes; elevated IL-17 is nonspecific; beta-2 microglobulin elevation occurs in lymphomatous meningitis. The CD4+/CD8+ ratio with activation markers specifically reflects the immunologic mechanism of checkpoint inhibitor toxicity.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Metastatic melanoma on ipilimumab + nivolumab, acute meningitic presentation, lymphocytic CSF pleocytosis with high protein, negative Gram stain, leptomeningeal enhancement, and negative CSF cytology/flow for malignancy. The question explicitly asks which *additional* CSF finding best supports an immune checkpoint inhibitor–mediated aseptic meningitis over infectious or neoplastic causes.\\nChoice D (CD4+/CD8+ T cell ratio >4:1 with activated phenotype) is most consistent with the known mechanism of CTLA-4/PD-1 blockade—enhanced, activated CD4+ T‑cell responses. Other options point to alternative etiologies: A (elevated ADA) toward tuberculous meningitis; B (oligoclonal bands) toward MS or chronic infection and is not specific; C (IL‑17) is nonspecific and not a standard diagnostic marker here; E (beta‑2 microglobulin) toward lymphomatous meningitis. Thus D is uniquely best and aligns with the rationale.\\nMain logical issue(s): None; discrimination is clear and choices are comparable.\\nMain medical accuracy issue(s): Minor—IL‑17 may be involved in autoimmunity but is indeed nonspecific and not used diagnostically.\\nMinimal fix: Option D could explicitly mention HLA‑DR/CD69 expression to mirror the explanation (e.g., “CD4+/CD8+ ratio >4:1 with HLA‑DR+ activated T‑cell phenotype”).\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Metastatic melanoma on ipilimumab + nivolumab, acute meningitic presentation, lymphocytic CSF pleocytosis with high protein, negative Gram stain, leptomeningeal enhancement, and negative CSF cytology/flow for malignancy. The question explicitly asks which *additional* CSF finding best supports an immune checkpoint inhibitor–mediated aseptic meningitis over infectious or neoplastic causes.\nChoice D (CD4+/CD8+ T cell ratio >4:1 with activated phenotype) is most consistent with the known mechanism of CTLA-4/PD-1 blockade—enhanced, activated CD4+ T‑cell responses. Other options point to alternative etiologies: A (elevated ADA) toward tuberculous meningitis; B (oligoclonal bands) toward MS or chronic infection and is not specific; C (IL‑17) is nonspecific and not a standard diagnostic marker here; E (beta‑2 microglobulin) toward lymphomatous meningitis. Thus D is uniquely best and aligns with the rationale.\nMain logical issue(s): None; discrimination is clear and choices are comparable.\nMain medical accuracy issue(s): Minor—IL‑17 may be involved in autoimmunity but is indeed nonspecific and not used diagnostically.\nMinimal fix: Option D could explicitly mention HLA‑DR/CD69 expression to mirror the explanation (e.g., “CD4+/CD8+ ratio >4:1 with HLA‑DR+ activated T‑cell phenotype”).", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-003", "question": "A 6-month-old infant presents with progressive hypotonia, poor feeding, and developmental regression over 2 weeks. Parents report a recent upper respiratory infection. Examination reveals absent deep tendon reflexes, tongue fasciculations, and paradoxical breathing. EMG shows fibrillation potentials and reduced motor unit recruitment. Genetic testing for SMN1 deletions is negative. CSF protein is markedly elevated at 280 mg/dL. Which of the following is the most likely diagnosis?", "options": ["Infantile-onset Pompe disease", "Acute motor axonal neuropathy variant of Guillain-Barré syndrome", "Spinal muscular atrophy type 1 with atypical genetics", "Infantile botulism", "Cytomegalovirus-associated polyradiculopathy"], "answer": "B", "answer_index": 1, "explanation": "The combination of acute/subacute onset following infection, areflexia, tongue fasciculations (cranial nerve involvement), paradoxical breathing, EMG showing denervation, and markedly elevated CSF protein with albuminocytologic dissociation strongly suggests acute motor axonal neuropathy (AMAN), a GBS variant. SMA type 1 would have positive SMN1 testing in >95% of cases and insidious onset. Infantile botulism shows decremental response on repetitive stimulation and normal CSF. Pompe disease shows myopathic EMG changes. CMV polyradiculopathy typically occurs in immunocompromised patients.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 6‑month-old with acute/subacute (2 weeks) progressive hypotonia, poor feeding, developmental regression after URI; areflexia; paradoxical breathing; EMG with fibrillation potentials and reduced motor unit recruitment (motor axonal involvement); markedly elevated CSF protein (albuminocytologic dissociation); negative SMN1 testing. This pattern strongly supports an acute motor neuropathy/GBS spectrum, particularly AMAN.\\nOption analysis: (B) fits acute postinfectious course, areflexia, high CSF protein, and motor axonal EMG. (A) Pompe disease usually has a more insidious course, cardiomegaly, and myopathic EMG, not albuminocytologic dissociation. (C) SMA type 1 is typically chronic from early infancy, not acute postinfectious, and SMN1 deletions are present in >95%; CSF protein is not classically very high. (D) Infantile botulism causes descending paralysis, constipation, pupillary/autonomic features, normal CSF, and characteristic EMG (decremental/incremental responses), not albuminocytologic dissociation. (E) CMV polyradiculopathy is mainly in immunocompromised hosts and typically has sensory and root pain findings.\\nMain issues: Tongue fasciculations are more classic for SMA than GBS, but cranial motor involvement is plausible and does not outweigh the stronger GBS features.\\nMinimal fix: Remove “tongue fasciculations” or rephrase as “bulbar weakness” to better match GBS and avoid SMA confusion.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 6‑month-old with acute/subacute (2 weeks) progressive hypotonia, poor feeding, developmental regression after URI; areflexia; paradoxical breathing; EMG with fibrillation potentials and reduced motor unit recruitment (motor axonal involvement); markedly elevated CSF protein (albuminocytologic dissociation); negative SMN1 testing. This pattern strongly supports an acute motor neuropathy/GBS spectrum, particularly AMAN.\nOption analysis: (B) fits acute postinfectious course, areflexia, high CSF protein, and motor axonal EMG. (A) Pompe disease usually has a more insidious course, cardiomegaly, and myopathic EMG, not albuminocytologic dissociation. (C) SMA type 1 is typically chronic from early infancy, not acute postinfectious, and SMN1 deletions are present in >95%; CSF protein is not classically very high. (D) Infantile botulism causes descending paralysis, constipation, pupillary/autonomic features, normal CSF, and characteristic EMG (decremental/incremental responses), not albuminocytologic dissociation. (E) CMV polyradiculopathy is mainly in immunocompromised hosts and typically has sensory and root pain findings.\nMain issues: Tongue fasciculations are more classic for SMA than GBS, but cranial motor involvement is plausible and does not outweigh the stronger GBS features.\nMinimal fix: Remove “tongue fasciculations” or rephrase as “bulbar weakness” to better match GBS and avoid SMA confusion.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-004", "question": "A 45-year-old man with acute myeloid leukemia undergoes allogeneic hematopoietic stem cell transplantation. On day +14, he develops fever, hypoxemia, and diffuse pulmonary infiltrates. Bronchoalveolar lavage shows hemorrhagic return with progressively bloodier aliquots. DAD is seen on transbronchial biopsy. Galactomannan, beta-D-glucan, and respiratory viral panel are negative. He is on tacrolimus with therapeutic levels. Which of the following findings would most strongly support a diagnosis of diffuse alveolar hemorrhage due to transplant-associated thrombotic microangiopathy rather than idiopathic pneumonia syndrome?", "options": ["Elevated serum lactate dehydrogenase with schistocytes on peripheral smear", "Presence of hemosiderin-laden macrophages in BAL fluid", "Concurrent acute kidney injury with proteinuria", "Elevated plasma-free hemoglobin with decreased haptoglobin", "Refractory thrombocytopenia despite platelet transfusions"], "answer": "E", "answer_index": 4, "explanation": "Transplant-associated thrombotic microangiopathy (TA-TMA) characteristically shows refractory thrombocytopenia that fails to increment appropriately with platelet transfusions due to ongoing platelet consumption in microthrombi. While elevated LDH, schistocytes, and decreased haptoglobin occur in both TA-TMA and other hemolytic processes, and AKI can occur in multiple post-transplant complications, the specific finding of platelet refractoriness distinguishes TA-TMA. Hemosiderin-laden macrophages simply confirm alveolar hemorrhage without indicating etiology. Idiopathic pneumonia syndrome does not cause platelet refractoriness.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible, with element of miskey)  \\nVerdict on keyed answer: Not uniquely determinable; key likely suboptimal/borderline miskeyed.\\n\\nKey stem clues: Recent allogeneic HSCT (day +14), fever, hypoxemia, diffuse infiltrates, BAL with progressively bloodier aliquots and DAD → diffuse alveolar hemorrhage. Question asks for finding that most strongly supports DAH due to **TA-TMA vs idiopathic pneumonia syndrome (IPS)**. IPS is a lung-limited inflammatory syndrome and should not produce systemic microangiopathy.\\n\\nProblem: Several options (A, C, D, E) describe systemic microangiopathic/hemolytic features that would be highly suggestive of TA-TMA and not IPS. The explanation asserts platelet refractoriness is “specific,” but in practice IPS should not cause MAHA (LDH/schistocytes, plasma-free Hgb, low haptoglobin) or classic TMA-type AKI either; these would also strongly support TA-TMA over IPS. No evidence is given that E is clearly more discriminating than A or D. Thus ≥3 options are reasonably defensible.\\n\\nMedical accuracy: The general associations for TA-TMA and IPS are sound, but the claim of relative specificity of platelet refractoriness over MAHA markers is overstated.\\n\\nMinimal fix: Reword options to group general MAHA findings together and contrast with uniquely TA-TMA platelet refractoriness, or explicitly state that hemolysis labs are nonspecific in this scenario and adjust key/explanation accordingly.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible, with element of miskey)  \nVerdict on keyed answer: Not uniquely determinable; key likely suboptimal/borderline miskeyed.\n\nKey stem clues: Recent allogeneic HSCT (day +14), fever, hypoxemia, diffuse infiltrates, BAL with progressively bloodier aliquots and DAD → diffuse alveolar hemorrhage. Question asks for finding that most strongly supports DAH due to **TA-TMA vs idiopathic pneumonia syndrome (IPS)**. IPS is a lung-limited inflammatory syndrome and should not produce systemic microangiopathy.\n\nProblem: Several options (A, C, D, E) describe systemic microangiopathic/hemolytic features that would be highly suggestive of TA-TMA and not IPS. The explanation asserts platelet refractoriness is “specific,” but in practice IPS should not cause MAHA (LDH/schistocytes, plasma-free Hgb, low haptoglobin) or classic TMA-type AKI either; these would also strongly support TA-TMA over IPS. No evidence is given that E is clearly more discriminating than A or D. Thus ≥3 options are reasonably defensible.\n\nMedical accuracy: The general associations for TA-TMA and IPS are sound, but the claim of relative specificity of platelet refractoriness over MAHA markers is overstated.\n\nMinimal fix: Reword options to group general MAHA findings together and contrast with uniquely TA-TMA platelet refractoriness, or explicitly state that hemolysis labs are nonspecific in this scenario and adjust key/explanation accordingly.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-005", "question": "A 3-year-old girl presents with acute onset right-sided weakness and slurred speech. CT head is negative for hemorrhage. MRI reveals acute left middle cerebral artery territory infarction. Echocardiogram shows no structural abnormalities or vegetations. Hypercoagulability workup including protein C, protein S, antithrombin III, factor V Leiden, and prothrombin gene mutation are normal. Hemoglobin electrophoresis is normal. She had chickenpox 6 weeks ago. Cerebral angiography shows focal stenosis of the left distal internal carotid artery with a \"beaded\" appearance. Which of the following is the most appropriate long-term management?", "options": ["Lifelong warfarin anticoagulation", "Aspirin therapy for 2 years with serial vascular imaging", "Immediate surgical bypass of the stenotic segment", "High-dose intravenous immunoglobulin monthly", "Indefinite dual antiplatelet therapy with aspirin and clopidogrel"], "answer": "B", "answer_index": 1, "explanation": "This presentation is classic for post-varicella arteriopathy (transient cerebral arteriopathy), which causes focal stenosis of large intracranial arteries following VZV infection. The condition is typically monophasic and self-limiting, with arterial changes stabilizing or improving over 6-24 months. Current guidelines recommend aspirin therapy for approximately 2 years with serial vascular imaging to monitor for progression or resolution. Anticoagulation is not superior to antiplatelet therapy and carries higher bleeding risk. Surgical bypass is not indicated for this typically self-resolving condition. IVIG has no established role in post-varicella arteriopathy.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 3-year-old with acute ischemic stroke; imaging shows left MCA infarct; negative hemorrhage and cardiac/hypercoagulable workup; history of varicella 6 weeks prior; cerebral angiography with focal distal ICA stenosis and ‘beaded’ appearance. This is classic for transient cerebral/post-varicella arteriopathy, a monophasic, typically self-limited large-vessel vasculopathy in children.\\nAspirin monotherapy with serial vascular imaging for a limited period (often up to ~2 years) is standard long-term management; it balances secondary stroke prevention with low bleeding risk and allows monitoring for stabilization/resolution.\\nOption A (lifelong warfarin) is excessive and not evidence-based for this condition; anticoagulation is not superior to antiplatelets and has higher bleeding risk. Option C (immediate surgical bypass) is inappropriate for a usually self-resolving focal stenosis. Option D (monthly IVIG) lacks evidence for routine management. Option E (indefinite dual antiplatelet therapy) provides no proven additional benefit and increases bleeding risk.\\nMain medical accuracy issues: Minor—duration (“2 years”) is somewhat guideline/center-dependent but within accepted practice. Minimal fix: Add wording such as “for up to 2 years” or “for 1–2 years” to reflect practice variability while keeping aspirin plus serial imaging as the clear best answer.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 3-year-old with acute ischemic stroke; imaging shows left MCA infarct; negative hemorrhage and cardiac/hypercoagulable workup; history of varicella 6 weeks prior; cerebral angiography with focal distal ICA stenosis and ‘beaded’ appearance. This is classic for transient cerebral/post-varicella arteriopathy, a monophasic, typically self-limited large-vessel vasculopathy in children.\nAspirin monotherapy with serial vascular imaging for a limited period (often up to ~2 years) is standard long-term management; it balances secondary stroke prevention with low bleeding risk and allows monitoring for stabilization/resolution.\nOption A (lifelong warfarin) is excessive and not evidence-based for this condition; anticoagulation is not superior to antiplatelets and has higher bleeding risk. Option C (immediate surgical bypass) is inappropriate for a usually self-resolving focal stenosis. Option D (monthly IVIG) lacks evidence for routine management. Option E (indefinite dual antiplatelet therapy) provides no proven additional benefit and increases bleeding risk.\nMain medical accuracy issues: Minor—duration (“2 years”) is somewhat guideline/center-dependent but within accepted practice. Minimal fix: Add wording such as “for up to 2 years” or “for 1–2 years” to reflect practice variability while keeping aspirin plus serial imaging as the clear best answer.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-006", "question": "A 62-year-old man with small cell lung cancer develops progressive proximal weakness over 3 months. He has difficulty rising from chairs and climbing stairs. Examination reveals proximal muscle weakness (3/5), preserved reflexes, and no sensory deficits. CK is 4,200 U/L. EMG shows myopathic changes with fibrillation potentials. Muscle biopsy reveals necrotic and regenerating fibers with minimal inflammatory infiltrate. Testing for anti-Jo-1, anti-Mi-2, anti-SRP, and anti-MDA5 antibodies is negative. Which antibody is most likely to be positive in this patient?", "options": ["Anti-HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase)", "Anti-TIF1-gamma (transcription intermediary factor 1-gamma)", "Anti-NXP-2 (nuclear matrix protein 2)", "Anti-SAE (small ubiquitin-like modifier activating enzyme)", "Anti-HMGCR antibodies with concurrent anti-SRP positivity"], "answer": "B", "answer_index": 1, "explanation": "Anti-TIF1-gamma antibodies are strongly associated with malignancy-associated dermatomyositis/inflammatory myopathy, particularly in adults over 40 with underlying cancer. Small cell lung cancer is a known associated malignancy. The biopsy showing necrotizing features with minimal inflammation is consistent with immune-mediated necrotizing myopathy, which can occur with TIF1-gamma positivity in cancer-associated cases. Anti-HMGCR is associated with statin exposure and necrotizing myopathy but not specifically with malignancy. Anti-NXP-2 is associated with calcinosis and juvenile dermatomyositis. Anti-SAE is associated with dermatomyositis with systemic features but lower malignancy risk.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple answers defensible, borderline miskey/underspecified)\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues: 62-year-old man, known small cell lung cancer, subacute proximal weakness, high CK, EMG myopathic, biopsy with necrotic/regenerating fibers and minimal inflammation → immune-mediated necrotizing myopathy associated with malignancy. Serology negative for Jo-1, Mi-2, SRP, MDA5.\\nThe explanation links this to anti–TIF1-γ, but TIF1-γ is classically a dermatomyositis-associated cancer antibody, usually with clear DM rash and more typical inflammatory myopathy histology, not minimal inflammation necrotizing myopathy. By contrast, anti-HMGCR is the canonical necrotizing myopathy antibody and can be malignancy-associated (though better known for statin exposure); the stem gives no statin or rash information to resolve this conflict. Thus both A (anti-HMGCR) and B (anti–TIF1-γ) are reasonably defensible, and the provided rationale partly contradicts standard associations for necrotizing myopathy.\\nMain medical accuracy issue: overstatement of TIF1-γ association with purely necrotizing myopathy and underplaying malignancy links of HMGCR; histology is more typical of HMGCR- or SRP-related disease.\\nMinimal fix: Add explicit dermatomyositis rash and classic DM biopsy changes, or change biopsy description to an inflammatory myopathy, to clearly favor anti–TIF1-γ over anti-HMGCR.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible, borderline miskey/underspecified)\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues: 62-year-old man, known small cell lung cancer, subacute proximal weakness, high CK, EMG myopathic, biopsy with necrotic/regenerating fibers and minimal inflammation → immune-mediated necrotizing myopathy associated with malignancy. Serology negative for Jo-1, Mi-2, SRP, MDA5.\nThe explanation links this to anti–TIF1-γ, but TIF1-γ is classically a dermatomyositis-associated cancer antibody, usually with clear DM rash and more typical inflammatory myopathy histology, not minimal inflammation necrotizing myopathy. By contrast, anti-HMGCR is the canonical necrotizing myopathy antibody and can be malignancy-associated (though better known for statin exposure); the stem gives no statin or rash information to resolve this conflict. Thus both A (anti-HMGCR) and B (anti–TIF1-γ) are reasonably defensible, and the provided rationale partly contradicts standard associations for necrotizing myopathy.\nMain medical accuracy issue: overstatement of TIF1-γ association with purely necrotizing myopathy and underplaying malignancy links of HMGCR; histology is more typical of HMGCR- or SRP-related disease.\nMinimal fix: Add explicit dermatomyositis rash and classic DM biopsy changes, or change biopsy description to an inflammatory myopathy, to clearly favor anti–TIF1-γ over anti-HMGCR.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-007", "question": "A 28-year-old woman at 32 weeks gestation presents with severe headache, visual changes, and right upper quadrant pain. Blood pressure is 178/112 mmHg. Laboratory studies show platelets 62,000/μL, AST 342 U/L, ALT 298 U/L, LDH 890 U/L, creatinine 1.8 mg/dL, and peripheral smear with schistocytes. Urinalysis shows 3+ protein. She receives magnesium sulfate and labetalol. Despite delivery 6 hours later, her platelet count drops to 28,000/μL and creatinine rises to 3.2 mg/dL over the next 48 hours. ADAMTS13 activity returns at 68%. Which of the following is the most appropriate next step in management?", "options": ["Initiate therapeutic plasma exchange", "Administer eculizumab", "Begin rituximab infusion", "Transfuse platelets to maintain count above 50,000/μL", "Continue supportive care with expectant management"], "answer": "B", "answer_index": 1, "explanation": "This patient has pregnancy-associated atypical hemolytic uremic syndrome (aHUS), evidenced by persistent/worsening microangiopathic hemolytic anemia and renal failure after delivery with ADAMTS13 activity >10% (ruling out TTP). Complement-mediated aHUS can be triggered by pregnancy and does not resolve with delivery alone. Eculizumab, a C5 complement inhibitor, is the treatment of choice for aHUS. Plasma exchange is first-line for TTP (ADAMTS13 <10%) but less effective in aHUS. Rituximab targets B cells and is used for autoimmune TTP. Platelet transfusion is relatively contraindicated in TMA. Expectant management risks progressive renal failure.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Third-trimester pregnant patient with severe hypertension and classic HELLP/preeclampsia features initially, then persistent/worsening thrombocytopenia, microangiopathic hemolytic anemia (schistocytes, high LDH), and renal failure despite delivery; ADAMTS13 activity 68% (well above the <10% threshold for TTP). These findings support pregnancy-triggered complement-mediated atypical HUS rather than TTP or resolving HELLP. Eculizumab, a C5 inhibitor, is current standard therapy for aHUS.\\nOption appraisal: A (therapeutic plasma exchange) is first-line for TTP and may be tried in unclear TMAs, but ADAMTS13 >10% and poor response post-delivery make aHUS more likely and plasmapheresis less effective than targeted complement inhibition. C (rituximab) is adjunctive in immune TTP, not aHUS. D (platelet transfusion) is relatively contraindicated in active TMA and reserved for life-threatening bleeding or procedures. E (supportive/expectant) is inappropriate given progression of renal injury and cytopenias.\\nMain medical accuracy issues: None significant; the ADAMTS13 cutoff and treatment distinctions align with accepted standards.\\nMinimal fix: Explicitly state that hemoglobin is low with elevated reticulocyte count to more clearly document ongoing microangiopathic hemolytic anemia, reinforcing the TMA diagnosis without changing the key.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Third-trimester pregnant patient with severe hypertension and classic HELLP/preeclampsia features initially, then persistent/worsening thrombocytopenia, microangiopathic hemolytic anemia (schistocytes, high LDH), and renal failure despite delivery; ADAMTS13 activity 68% (well above the <10% threshold for TTP). These findings support pregnancy-triggered complement-mediated atypical HUS rather than TTP or resolving HELLP. Eculizumab, a C5 inhibitor, is current standard therapy for aHUS.\nOption appraisal: A (therapeutic plasma exchange) is first-line for TTP and may be tried in unclear TMAs, but ADAMTS13 >10% and poor response post-delivery make aHUS more likely and plasmapheresis less effective than targeted complement inhibition. C (rituximab) is adjunctive in immune TTP, not aHUS. D (platelet transfusion) is relatively contraindicated in active TMA and reserved for life-threatening bleeding or procedures. E (supportive/expectant) is inappropriate given progression of renal injury and cytopenias.\nMain medical accuracy issues: None significant; the ADAMTS13 cutoff and treatment distinctions align with accepted standards.\nMinimal fix: Explicitly state that hemoglobin is low with elevated reticulocyte count to more clearly document ongoing microangiopathic hemolytic anemia, reinforcing the TMA diagnosis without changing the key.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-008", "question": "A 14-year-old boy with no significant medical history presents after a witnessed generalized tonic-clonic seizure lasting 2 minutes with spontaneous termination. He reports a 3-month history of early morning myoclonic jerks causing him to drop objects, which he attributed to clumsiness. EEG shows 4-6 Hz generalized polyspike-and-wave discharges with photosensitivity. MRI brain is normal. His father had similar episodes as a teenager that resolved. Which of the following medications should be specifically avoided in this patient?", "options": ["Levetiracetam", "Valproic acid", "Lamotrigine", "Carbamazepine", "Topiramate"], "answer": "D", "answer_index": 3, "explanation": "This patient has juvenile myoclonic epilepsy (JME), characterized by myoclonic jerks (especially morning), generalized tonic-clonic seizures, photosensitivity, and generalized polyspike-and-wave on EEG. Carbamazepine and other sodium channel blockers (phenytoin, oxcarbazepine) can paradoxically worsen myoclonic and absence seizures in genetic generalized epilepsies like JME by enhancing thalamocortical synchronization. Valproic acid is highly effective but avoided in women of childbearing potential due to teratogenicity. Levetiracetam and lamotrigine are appropriate alternatives. Topiramate has broad-spectrum efficacy including in JME.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 14-year-old boy, early-morning myoclonic jerks with dropped objects, generalized tonic-clonic seizure, normal MRI, EEG with 4–6 Hz generalized polyspike-and-wave and photosensitivity, positive family history. These findings are classic for juvenile myoclonic epilepsy (JME), a genetic generalized epilepsy syndrome.\\nCarbamazepine (D) is well known to exacerbate myoclonic and absence seizures in generalized epilepsies like JME because as a narrow-spectrum sodium channel blocker it can worsen generalized seizure types. By contrast, valproic acid, levetiracetam, lamotrigine, and topiramate are considered broad-spectrum agents suitable for generalized epilepsies, including JME (with usual caveats about valproate in females of childbearing potential, which is not relevant in this 14-year-old boy). Thus D is uniquely best as the drug to specifically avoid.\\nThere are no internal contradictions, and no alternative choice is similarly defensible as “should be avoided” in this specific patient.\\nMain medical accuracy: The syndrome description, EEG features, and pharmacology/clinical guidance are all accurate and current. \\nMinimal fix: None strictly required; optionally, adding the phrase “due to risk of seizure worsening” to the stem could further clarify why a drug is being avoided.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 14-year-old boy, early-morning myoclonic jerks with dropped objects, generalized tonic-clonic seizure, normal MRI, EEG with 4–6 Hz generalized polyspike-and-wave and photosensitivity, positive family history. These findings are classic for juvenile myoclonic epilepsy (JME), a genetic generalized epilepsy syndrome.\nCarbamazepine (D) is well known to exacerbate myoclonic and absence seizures in generalized epilepsies like JME because as a narrow-spectrum sodium channel blocker it can worsen generalized seizure types. By contrast, valproic acid, levetiracetam, lamotrigine, and topiramate are considered broad-spectrum agents suitable for generalized epilepsies, including JME (with usual caveats about valproate in females of childbearing potential, which is not relevant in this 14-year-old boy). Thus D is uniquely best as the drug to specifically avoid.\nThere are no internal contradictions, and no alternative choice is similarly defensible as “should be avoided” in this specific patient.\nMain medical accuracy: The syndrome description, EEG features, and pharmacology/clinical guidance are all accurate and current. \nMinimal fix: None strictly required; optionally, adding the phrase “due to risk of seizure worsening” to the stem could further clarify why a drug is being avoided.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-009", "question": "A 55-year-old man is admitted to the ICU with septic shock secondary to necrotizing pancreatitis. Despite adequate fluid resuscitation and norepinephrine at 0.5 mcg/kg/min, his MAP remains 58 mmHg. Vasopressin 0.04 units/min is added. Central venous oxygen saturation is 58%, lactate is 6.2 mmol/L, and cardiac index by thermodilution is 2.0 L/min/m². Echocardiogram shows hyperdynamic left ventricle with LVEF 70% and small, underfilled chambers. Which of the following is the most appropriate next intervention?", "options": ["Add dobutamine for inotropic support", "Administer additional crystalloid bolus", "Initiate phenylephrine infusion", "Add epinephrine as third vasopressor", "Begin hydrocortisone 50 mg IV every 6 hours"], "answer": "B", "answer_index": 1, "explanation": "Despite initial resuscitation, the echocardiographic findings of hyperdynamic LV with small, underfilled chambers indicate persistent hypovolemia. The low ScvO2 (58%) and elevated lactate suggest inadequate oxygen delivery. In the setting of distributive shock with evidence of preload deficiency, additional volume resuscitation is indicated before adding further vasopressors. Dobutamine would be inappropriate given the already hyperdynamic state. Phenylephrine causes pure vasoconstriction without inotropy and may worsen cardiac output. Epinephrine could be considered after optimizing preload. Hydrocortisone is indicated for refractory shock but addressing hypovolemia takes priority.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Septic shock on high-dose norepinephrine plus vasopressin; MAP still 58 mmHg. ScvO2 58% and lactate 6.2 indicate inadequate oxygen delivery. Cardiac index 2.0 L/min/m² is low, but echo shows hyperdynamic LV with small, underfilled chambers, indicating low preload rather than pump failure. This pattern is classic for under-resuscitated distributive shock where volume status remains inadequate despite “adequate” initial fluids.\\nGiven these findings, the next intervention should be further fluid resuscitation (B). Dobutamine (A) is inappropriate because LVEF is already hyperdynamic; inotropy would not fix an underfilled ventricle and may worsen tachycardia/oxygen demand. Phenylephrine (C) is a pure alpha-agonist that can further impair cardiac output and is not preferred in septic shock. Epinephrine (D) is reasonable only after optimizing preload. Hydrocortisone (E) may be added in refractory septic shock but is not the immediate priority when there is clear evidence of hypovolemia.\\nMain medical accuracy issue: Minor—cardiac index is low-normal, but consistent with hypovolemia plus vasoconstriction.\\nMinimal fix: Clarify that dynamic or cumulative fluid balance suggests ongoing volume responsiveness, supporting additional crystalloids.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Septic shock on high-dose norepinephrine plus vasopressin; MAP still 58 mmHg. ScvO2 58% and lactate 6.2 indicate inadequate oxygen delivery. Cardiac index 2.0 L/min/m² is low, but echo shows hyperdynamic LV with small, underfilled chambers, indicating low preload rather than pump failure. This pattern is classic for under-resuscitated distributive shock where volume status remains inadequate despite “adequate” initial fluids.\nGiven these findings, the next intervention should be further fluid resuscitation (B). Dobutamine (A) is inappropriate because LVEF is already hyperdynamic; inotropy would not fix an underfilled ventricle and may worsen tachycardia/oxygen demand. Phenylephrine (C) is a pure alpha-agonist that can further impair cardiac output and is not preferred in septic shock. Epinephrine (D) is reasonable only after optimizing preload. Hydrocortisone (E) may be added in refractory septic shock but is not the immediate priority when there is clear evidence of hypovolemia.\nMain medical accuracy issue: Minor—cardiac index is low-normal, but consistent with hypovolemia plus vasoconstriction.\nMinimal fix: Clarify that dynamic or cumulative fluid balance suggests ongoing volume responsiveness, supporting additional crystalloids.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed125-010", "question": "A 7-year-old boy presents with 2 weeks of progressive gait instability and tremor. Examination reveals opsoclonus (chaotic, multidirectional saccadic eye movements), myoclonus, and truncal ataxia. MRI brain and spine are normal. CSF shows mild lymphocytic pleocytosis. CT chest/abdomen/pelvis reveals a paraspinal mass. Urine catecholamines are elevated. Tumor resection is planned. Which of the following additional findings would indicate the WORST long-term neurodevelopmental prognosis despite tumor treatment?", "options": ["Presence of anti-Hu antibodies in serum", "CSF oligoclonal bands with elevated IgG index", "Age less than 3 years at symptom onset", "Tumor histology showing neuroblastoma with MYCN amplification", "Delayed initiation of immunotherapy beyond 4 weeks from diagnosis"], "answer": "C", "answer_index": 2, "explanation": "Opsoclonus-myoclonus-ataxia syndrome (OMS) associated with neuroblastoma has variable neurodevelopmental outcomes. Younger age at onset (particularly <3 years) is paradoxically associated with worse long-term cognitive and behavioral outcomes, likely due to the impact of neuroinflammation on the developing brain during critical periods. While MYCN amplification indicates aggressive tumor biology, it does not correlate with neurological outcomes. Anti-Hu antibodies are rare in pediatric OMS. CSF inflammatory markers and treatment delays affect outcomes but age remains the strongest predictor of neurodevelopmental sequelae.", "generator_model": "claude-opus-4-5-20251101", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 7-year-old with opsoclonus-myoclonus-ataxia syndrome (OMS), paraspinal neuroblastoma, and question about worst long-term neurodevelopmental prognosis despite tumor treatment. The options mix tumor biology, autoantibodies, age, CSF inflammation, and treatment timing.\\nAge <3 years at onset (choice C) is well described as a strong adverse prognostic factor for long-term cognitive/behavioral outcome in neuroblastoma-associated OMS, due to vulnerability of early brain development to neuroinflammation. MYCN amplification (D) predicts oncologic risk, not specifically neurodevelopmental outcome in OMS. Anti-Hu antibodies (A) are uncommon in pediatric OMS and more typical of paraneoplastic encephalomyelitis in adults; no evidence they trump age as a prognostic factor here. CSF oligoclonal bands/elevated IgG index (B) and delayed immunotherapy (E) can associate with worse outcomes, but current literature and the stem’s own rationale identify age at onset as the strongest predictor, making C the single best choice.\\nNo internal contradictions or clear alternative equally supported answers.\\nMain medical accuracy issue: none substantive; the teaching point is current. \\nMinimal fix: Cite a reference timeframe (e.g., \\\"current evidence suggests\\\") to support age as the dominant prognostic factor, but item is already acceptable.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 7-year-old with opsoclonus-myoclonus-ataxia syndrome (OMS), paraspinal neuroblastoma, and question about worst long-term neurodevelopmental prognosis despite tumor treatment. The options mix tumor biology, autoantibodies, age, CSF inflammation, and treatment timing.\nAge <3 years at onset (choice C) is well described as a strong adverse prognostic factor for long-term cognitive/behavioral outcome in neuroblastoma-associated OMS, due to vulnerability of early brain development to neuroinflammation. MYCN amplification (D) predicts oncologic risk, not specifically neurodevelopmental outcome in OMS. Anti-Hu antibodies (A) are uncommon in pediatric OMS and more typical of paraneoplastic encephalomyelitis in adults; no evidence they trump age as a prognostic factor here. CSF oligoclonal bands/elevated IgG index (B) and delayed immunotherapy (E) can associate with worse outcomes, but current literature and the stem’s own rationale identify age at onset as the strongest predictor, making C the single best choice.\nNo internal contradictions or clear alternative equally supported answers.\nMain medical accuracy issue: none substantive; the teaching point is current. \nMinimal fix: Cite a reference timeframe (e.g., \"current evidence suggests\") to support age as the dominant prognostic factor, but item is already acceptable.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]